Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Atopic Dermatitis
Interventions: Tilrekimig, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 11 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions: RO7204239, RO7204239 Matching Placebo, Tirzepatide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more

Conditions: Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions: Levosimendan, Matching Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 16
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more

Conditions: Healthy Volunteers
Interventions: AJ302-IM, Placebo; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acute Gout
Interventions: Canakinumab, Triamcinolone acetonide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more

Conditions: Dengue
Interventions: TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Prurigo Nodularis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more

Conditions: Eosinophilic Esophagitis
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Intracerebral Hemorrhage
Interventions: Recombinant Factor VIIa, Biological/Vaccine: Placebo; Biological
Lead sponsor: Joseph Broderick, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 49
States / cities: Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 39 more

Conditions: Spinal Muscular Atrophy (SMA)
Interventions: RO7204239, Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Severe Asthma
Interventions: Verekitug (UPB-101), Placebo; Drug
Lead sponsor: Upstream Bio Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 55
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 47 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebos; Drug
Lead sponsor: Sabyasachi Sen; Other
Eligibility: 20 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Prevention of Infection With HIV-1
Interventions: ibalizumab (biologic/MAb) for SC Injection or placebo; Biological
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Birmingham, Alabama • Long Beach, California • San Francisco, California + 3 more

Conditions: Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions: Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 65 Years and older
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more

Conditions: Sciatica, Radiculopathy
Interventions: epidural steroid injection, Sham epidural steroid injection, Gabapentin, Placebo gabapentin; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 17 Years to 100 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Bethesda, Maryland

Conditions: Cerebral Palsy
Interventions: tSCS, 5-Azacitidine, Mannitol, Functional Activity Training; Other · Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 4 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Migraine
Interventions: Galcanezumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 862 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 80
States / cities: Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 72 more

Conditions: Systemic Lupus Erythematosus
Interventions: Herpes Zoster Subunit (HZ/su) Vaccine, Placebo; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New York, New York • Oklahoma City, Oklahoma

Conditions: Healthy
Interventions: PER977, Placebo, Heparin Sodium; Drug
Lead sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more

Conditions: Allergic Conjunctivitis, Allergic Rhinitis
Interventions: Dose Level 1, Dose Level 2, Placebo; Biological
Lead sponsor: Woodmont Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Cleft Palates
Interventions: Unasyn, saline solution; Drug · Other
Lead sponsor: Joseph Losee; Other
Eligibility: 3 Months to 18 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJ302-IM in Healthy Volunteers

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Steroids Versus Gabapentin

tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy

Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study

Safety of the Herpes Zoster Subunit Vaccine in Lupus

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections

Preventing Complications in Cleft Palate Repair With Antibiotics